Dana-Farber Leads Kadcyla ATEMPT Study in HER2-Positive Breast Cancer

Article

Experts review an innovative study, called the ATEMPT study, which looks at adjuvant T-DM1 in women with HER2-positive breast cancer.

Experts review an innovative study, called the ATEMPT study, which looks at adjuvant T-DM1 in women with HER2-positive breast cancer.

Related Videos
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Sue Friedman in an interview with CURE
Dr. Giles in an interview with CURE
Related Content